Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

26.41 -0.52 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 984,890
Open 26.58
Bid (Size) 26.40 (10)
Ask (Size) 26.42 (20)
Prev. Close 26.93
Today's Range 25.91 - 26.86
52wk Range 20.67 - 53.58
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
From Guardant Health, Inc.
Via Business Wire

Performance

YTD
-2.19%
-2.19%
1 Month
-4.79%
-4.79%
3 Month
-25.21%
-25.21%
6 Month
-18.46%
-18.46%
1 Year
-49.16%
-49.16%

More News

Read More
Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring'
Via Benzinga
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
7 Analysts Have This to Say About Guardant Health
Via Benzinga
Earnings Scheduled For November 6, 2023
Via Benzinga
Why Is Cancer Blood Test-Focused Guardant Health Stock Trading Lower Today?
Via Benzinga
Guardant Health to Appeal Federal District Court Verdict
From Guardant Health, Inc.
Via Business Wire
Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook
Via Benzinga
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming November Investor Conferences
From Guardant Health, Inc.
Via Business Wire
The Latest Analyst Ratings for Guardant Health
Via Benzinga
Why Guardant Health Stock Popped Again Today
Via The Motley Fool
Analyst Expectations for Guardant Health's Future
Via Benzinga
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
From Guardant Health, Inc.
Via Business Wire
Bull Of The Day: NeoGenomics
Via Talk Markets
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
From Guardant Health, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Via FinancialNewsMedia
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
From Guardant Health, Inc.
Via Business Wire
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
Via The Motley Fool
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
Via The Motley Fool
Why Guardant Health Stock Jumped 15% This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.